It is as long as the FDA can operate flexibly enough to not spend extra time where they shouldn’t. If they can’t, as seems to have been the case historically, then it’s best overall from a mortality and longevity perspective if they err on the side of faster releases. Note that faster operation also means they can more quickly act on feedback from the market and medical practitioners post release.